cagrilintide novo Wegovy Maker Nordisk Files for FDA Approval of Obesity Drug CagriSema cagrilintide weight loss Amylin Injectable

The peptide is not FDA-approved for any medical condition and is typically used as a research compound or through compounding pharmacies

Inositol transports and removes fat from the liver in a method similar to other amino acids

Across more than 100 preclinical publications many from a single research group led by Sikiri and colleagues the peptide has demonstrated healing effects on tendon, muscle, bone, nerve, and gut tissue, often with no reported acute toxicity even at doses far exceeding those proposed for practical use

The Pharmacy Compounding Advisory Committee is advisory only it met July 2324, 2026 (docket FDA-2025-N-6895) to review nominations and make recommendations, and the FDA issues any final rule later, typically 618 months afterward

The peptide reduces the rate at which the body creates new fat from food, particularly when carbohydrate intake is high